- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
ISA247 is safe, effective treatment for psoriasis
Waterloo, Ontario, Canada - A phase 3 trial shows ISA247 to be safe and effective in the treatment of moderate to severe plaque psoriasis, Medical News Today reports.
Waterloo, Ontario, Canada
- A phase 3 trial shows ISA247 to be safe and effective in the treatment of moderate to severe plaque psoriasis, Medical News Today reports.
The results, published April 18 in The Lancet, showed the drug dose and response relationship to be almost linear, suggesting patients can be accurately dosed to achieve a clinical response while minimizing side effects.
ISA247, a new type of calcineurin inhibitor, was investigated in a placebo-controlled randomized trial on 451 patients aged 18 to 65, with plaque psoriasis covering at least 10 percent of the body, according to Medical News Today.
Researchers found that when the ISA247 dose was higher, it performed better.
